Lincoln Pharmaceuticals strengthens on receiving patent for Diclofenac Rectal Spray | | Udaipur News | Udaipur Latest News | udaipur local news । Udaipur Updates
Home / BUSINESS / Lincoln Pharmaceuticals strengthens on receiving patent for Diclofenac Rectal Spray

Lincoln Pharmaceuticals strengthens on receiving patent for Diclofenac Rectal Spray

Lincoln Pharmaceuticals is currently trading at Rs. 161.25, up by 7.70 points or 5.01% from its previous closing of Rs. 153.55 on the BSE.

The scrip opened at Rs. 157.20 and has touched a high and low of Rs. 166.05 and Rs. 153.70 respectively. So far 19364 shares were traded on the counter.

The BSE group ‘B’ stock of face value Rs. 10 has touched a 52 week high of Rs. 275.70 on 14-Nov-2018 and a 52 week low of Rs. 124.40 on 29-Aug-2019.

Last one week high and low of the scrip stood at Rs. 166.05 and Rs. 143.30 respectively. The current market cap of the company is Rs. 308.00 crore.

The promoters holding in the company stood at 32.40%, while Institutions and Non-Institutions held 0.23% and 67.37% respectively.

Lincoln Pharmaceuticals has been awarded a patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray). The patent has been awarded by the Government of India for ‘A Novel Liquid Rectal Spray Dosage Form Containing Diclofenac and Its Pharmaceutically Active Salts’. This Patent is valid for 20 years.

The company has necessary approvals from Drug Controller General of India (DCGI) and planning to launch it in the Indian market by January 2020. The company is also planning to apply for a Global Patent for this novel solution.

Lincoln Pharmaceuticals is engaged in the manufacture and marketing of affordable therapeutic products. The product range of the company includes Tablets, Capsules, Injectable, Syrups and Ointments.

Please share this news